Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis. DESIGN: Prospective, randomised, double blind, double dummy, multicentre, parallel group study lasting 72 weeks. SETTING: 35 centres in six European countries. SUBJECTS: 496 patients aged 18 to 75 years with a clinical and mycological diagnosis of dermatophyte onychomycosis of the toenail. INTERVENTIONS: Study patients were randomly divided into four parallel groups to receive either terbinafine 250 mg a day for 12 or 16 weeks (groups T12 and T16) or itraconazole 400 mg a day for 1 week in every 4 weeks for 12 or 16 weeks (groups I3 and I4). MAIN OUTCOME MEASURES: Assessment of primary efficacy at week 72 was mycological cure, defined as negative results on microscopy and culture of samples from the target toenail. RESULTS: At week 72 the mycological cure rates were 75.7% (81/107) in the T12 group and 80. 8% (80/99) in the T16 group compared with 38.3% (41/107) in the I3 group and 49.1 % (53/108) in the I4 group. All comparisons (T12 v I3, T12 v I4, T16 v I3, T16 v I4) showed significantly higher cure rates in the terbinafine groups (all P<0.0001). Also, all secondary clinical outcome measures were significantly in favour of terbinafine at week 72. There were no differences in the number or type of adverse events recorded in the terbinafine or itraconazole groups. CONCLUSION: Continuous terbinafine is significantly more effective than intermittent itraconazole in the treatment of patients with toenail onychomycosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antifungal agents: An overview. Part I
Gupta, A. K., Sauder, D. N., & Shear, N. H. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81495-8 · Cited by 369
Doncker, P. D. (1996) · Archives of Dermatology · doi:10.1001/archderm.132.1.34 · Cited by 155
Bräutigam, M., Nolting, S., Schopf, R. E., & Weidinger, G. (1995) · BMJ · doi:10.1136/bmj.311.7010.919 · Cited by 143
Prevalence, morbidity, and cost of dermatologie diseases
Johnson, M.-L. T., Johnson, K. G., & Engel, A. (1984) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(84)80017-1 · Cited by 139
Backer, M. D., de Keyser, P., Vroey, C. D., & Lesaffre, E. M. E. H. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb15653.x · Cited by 132
PREVALENCE, MORBIDITY, AND COST OF DERMATOLOGICAL DISEASES
(1979) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12541101 · Cited by 97
Clayton, Y. M. (1994) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb06084.x · Cited by 79
Significance of Non-Dermatophyte Moulds and Yeasts in Onychomycosis
Ellis, D. H., Marley, J. E., Watson, A. B., & Williams, T. (2009) · Dermatology · doi:10.1159/000246184 · Cited by 65
Elewski, B. E. (1997) · Archives of Dermatology · doi:10.1001/archderm.1997.03890460143029 · Cited by 52
Cited by
Infections in Patients with Diabetes Mellitus
Joshi, N., Caputo, G. M., Weitekamp, M. R., & Karchmer, A. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412507 · Cited by 1,043
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
REVIEW ARTICLE: Toenail onychomycosis: an important global disease burden
Thomas, J., Jacobson, G. A., Narkowicz, C. K., Peterson, G. M., Burnet, H., & Sharpe, C. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01107.x · Cited by 327
Sigurgeirsson, B., Ólafsson, J. H., Steinsson, J. Þ., Paul, C., Billstein, S., & Evans, E. G. V. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.3.353 · Cited by 212
“It has previously been demonstrated in a randomized controlled, multicenter, double-blind, double-dummy study (the Lamisil vs Itraconazole in Onychomycosis [LION] study) that patients treated with continuous terbinafine achieved significantly superior mycological and clinical cure rates compared with patients treated…”
BackgroundMethodResultInfluentialSelf-citationCumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis
Gupta, A. K., Ryder, J. E., & Johnson, A. M. (2004) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05728.x · Cited by 163
Metadata
- Authors
- Evans, E. G. V., & Sigurgeirsson, B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1999-04-17
- Volume
- 318
- Issue
- 7190
- Pages
- 1031-1035
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1979941741
- Cited by
- 263
- References
- 9
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. https://app.cochat.ai/papers/10.1136/bmj.318.7190.1031
- The paper
- Evans, E. G. V., & Sigurgeirsson, B. (1999). Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ. https://doi.org/10.1136/bmj.318.7190.1031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.